# EDGAR Filing Document

**Accession Number:** 0001711279
**File Stem:** 0002114613-26-000003
**Filing Date:** 2026-3
**Character Count:** 7529
**Document Hash:** 25fc35081536f05cb80ec19665b76238
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002114613-26-000003.hdr.sgml**: 20260306

**ACCESSION NUMBER**: 0002114613-26-000003

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260301

**FILED AS OF DATE**: 20260306

**DATE AS OF CHANGE**: 20260306

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Goux Laurent Louis Jean
- **CENTRAL INDEX KEY:** 0002114613

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38210
- **FILM NUMBER:** 26732655

**MAIL ADDRESS:**
- **STREET 1:** 2100 WHARTON STREET
- **STREET 2:** SUITE 701
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Krystal Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001711279
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 821080209
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2100 WHARTON STREET
- **STREET 2:** SUITE 701
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203
- **BUSINESS PHONE:** (412) 586-5830

**MAIL ADDRESS:**
- **STREET 1:** 2100 WHARTON STREET
- **STREET 2:** SUITE 701
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203

## Exhibit 24.1

![](lauentsignedpoaforfiling001.jpg)

Exhibit 24.1

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Goux Laurent Louis Jean<br><sub>(Last) (First) (Middle)</sub><br>C/O KRYSTAL BIOTECH, INC.<br>2100 WHARTON STREET, SUITE 701<br><sub>(Street)</sub><br>PITTSBURGH, PA 15203<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Krystal Biotech, Inc. [ KRYS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP, Head of International_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 919 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2036-02-26 | Common Stock | 9050 | $275.64 | D |  |
| Restricted Stock Units | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 3628<sup>(3)</sup> | <sup>(4)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2035-02-27 | Common Stock | 7449 | $179.25 | D |  |
| Restricted Stock Units | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 891<sup>(3)</sup> | <sup>(4)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(7)</sup> | 2034-02-27 | Common Stock | 2367 | $159.47 | D |  |
| Restricted Stock Units | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 674<sup>(3)</sup> | <sup>(4)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(9)</sup> | 2033-02-27 | Common Stock | 4750 | $81.91 | D |  |
| Stock Option (Right to Buy) | <sup>(10)</sup> | 2032-02-27 | Common Stock | 2750 | $63.55 | D |  |
| Stock Option (Right to Buy) | <sup>(10)</sup> | 2031-09-29 | Common Stock | 19000 | $52.21 | D |  |

---

### Footnotes:

(1) The stock option was granted on February 27, 2026, and vests in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

(2) The restricted stock units ("RSUs") vest in four equal annual installments with the first installment vesting on February 27, 2027.

(3) The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.

(4) Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.

(5) The stock option was granted on February 28, 2025, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

(6) The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 28, 2025, subject to the Reporting Person's continued service through each applicable vesting date.

(7) The stock option was granted on February 29, 2024, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

(8) The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 29, 2024, subject to the Reporting Person's continued service through each applicable vesting date.

(9) The stock option was granted on February 28, 2023, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

(10) The stock option is fully vested.

**Remarks:**
Exhibit 24.1 Power of Attorney

**Signature:** /s/ Laurent Goux  
**Date:** 2026-03-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**